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Summary
Lymphocyte function-associated antigen 1/intercellular adhesion moleculer 1 (LFA-1/ICAM-1)- 
and very late antigen 4/vascular cell adhesion molecule 1 (VLA-4/VCAM-1)-mediated adhesion 
of T lymphocytes to endothelial cells (EC) can be regulated by increased expression of ICAM-1 
and VCAM-1 upon cytokine treatment of EC, or by activation of the integrin molecules LFA-1 
and VLA-4 on T cells. Here, we provide evidence that preferential usage of LFA-1 over VLA-4 
is yet another mechanism to control T cell adhesion. We observed that binding of activated 
T lymphocytes, as opposed to resting T cells, to EC is essentially mediated through LFA-1 and 
not through VLA-4. VLA-4-mediated adhesion of T cells to EC is only found when LFA-1 is 
not expressed or not functional, as observed for several T cell leukemia cell lines. These results 
suggest that LFA-l-mediated adhesion dominates and may downregulate VLA-4-mediated adhesion 
through an unidentified mechanism.
Adhesion of T lymphocytes to endothelium, lining the 
i i  blood vessels, is a crucial step in immune surveillance. 
It allows T lymphocytes to recirculate and migrate into sites 
of inflammation (1). Different adhesion receptors have been 
described to be involved in this process (2, 3). The integrins 
LFA-1 and very late antigen 4 (VLA-4), which are both ex­
pressed on T cells, have been reported to mediate binding 
to endothelial cells (EC) (4-7). One mechanism to regulate 
adhesion of T lymphocytes to endothelial cells involves acti­
vation of EC by inflammatory cytokines such as TNF-a, 
which results in a rapid increase in the expression of intercel­
lular adhesion molecule 1 (ICAM-1) and vascular cell adhe­
sion molecule 1 (VCAM-1), ligands of LFA-1 and VLA-4, 
respectively (3, 8). Recently, the activation state of these 
integrin molecules expressed by T cells also has been described 
to play an important role in the regulation of the adhesion 
function of these cells (9-13). Here we demonstrate that yet 
another mechanism can regulate cell adhesion. By using an 
antibody (NKI-L16) that recognizes an activation epitope 
(termed L16) on LFA-1 (9, 14), we observed that the func­
tional state of the LFA^l molecule, as reported by this anti­
body, determines if LFA-1 or VLA-4 is exploited by T cells 
to bind EC. The results suggest that, only when LFA-1 is 
not capable to mediate adhesion, VLA-4 is used by T lym­
phocytes to bind EC, pointing to a selective use of these adhe­
sion receptors by T cells.
Materials and Methods
Reagents and Antibodies, The mAbs used in this study were SPV- 
L7 directed against the a  chain of LFA-1 (CDlla; 15), NKI-L16 
directed against a Ca2+-dependent epitope on LFA-la (CDlla*; 
16), CLB LFA-1/1 reactive with the (32 chain (CD18; 16); F10.2 
(anti-ICAM-1, CD54); HP2/1 (anti-VLA-4, CD49d; 17); TS2/16 
directed against ¡31 (CD29; 18); 4B9 (anti-VCAM-1); and ENA-1 
(anti-endothelial leukocyte adhesion molecule 1 [ELAM-1]). Re­
agents used were human rTNF-a (100 U/ml; supernatant of cDNA- 
transfected COS cells), phorbol ester PM A (50 ng/ml; Sigma Chem­
ical Co., St. Louis, MO), and fibronectin (FN) (20 jug/ml; Sigma 
Chemical Co.).
Cells. The T cell clone JS136 used in this study was cultured 
as described previously (9). The LFA-l-deficient T cell clone (LAD 
6.6) was raised from PBL of a patient suffering from the leukocyte 
adhesion deficiency (LAD) syndrome (19) and was cultured under 
same conditions as T cell clone JS136. The human leukemic T cell 
lines Jurkat and CEM were cultured in Iscove’s medium containing 
5% FCS. A homogenous population of highly purified T lympho­
cytes was isolated by centrifugal elutriation (9), and cultured in 
Iscove’s medium containing 5% FCS and IL-2 (100 U/ml; Cetus 
Corp., Emeryville, CA) for 24 h. L-ICAM-1 cells were obtained 
by transfection of ICAM-1 cDNA into mouse fibroblast L cells. 
ICAM-1 expression was high (95%;'mean, 45) and remained 
throughout culture of the cells in the presence of Hygromycin B 
(200 jug/ml; Schering Research, Bloomfield, NJ). Human EC were 
isolated from umbilical vein by collagenase digestion, and cultured
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as described previously (20). Cells from passages one to three were 
used for adhesion experiments.
Clustering Assay. Binding of T cells to L-ICAM-1 cells was de­
termined by means of double fluorescence. Cells (106/ml) were 
stained with the green dye sulfofluorescein diacetate (SFDA; Mo­
lecular Probes, Junction City, OR) at a concentration of 5 /xg/ml 
or with the red dye Hydroethidine (HE; Polyscience Inc., War­
rington, PA) at a concentration of 3 ng/ml, as described previously 
(9). 105 red-labeled cells and 105 green-labeled cells were incubated 
at 37°C for different periods of time in Iscove’s medium containing
0.5% BSA, and stimulated with PM A (50 ng/ml). Subsequently, 
cells were fixed with 0.5% (wt/vol) paraformaldehyde, and heter­
otypic conjugates were measured by FACScan® analysis (Becton 
Dickinson Sc Co., Mountain View, CA). Data are representative 
of four experiments.
Adhesion Assay Human EC were seeded at 2 x 105 cells/ml 
in FN-coated (2 /xg/ml) 96-well plates and were stimulated for 24 h 
with human rTNF-o: (100 U/ml). Adhesion experiments were per­
formed as described previously (20). Briefly, 51Cr-labeled T cells 
were allowed to bind at 37°C for 30 min. The number of adherent 
T cells was quantified in a gamma counter. Results are expressed 
as the mean percentage of cells binding from triplicate wells. For 
inhibition studies, cells were preincubated (30 min, 4°C) with 1:100 
ascites dilution or 10 ptg/ml purified mAb. Data are representative, 
for four experiments. For adhesion experiments to VCAM-1, purified 
soluble VCAM-1 (21) (0.8 ¡j,g/ml) was coated for 16 h at 4°C. Sub­
sequently, wells were coated by 1% (wt/vol) BSA for 1 h at 37°C. 
T cell adhesion was performed under the same conditions as de­
scribed for EC.
Immunofluorescence. Cells were incubated for 30 min at 4°C in 
PBS, 0.5% (wt/vol) BSA, 0.2% azide with appropriate dilutions 
of the mAb, followed by incubation with FITC-labeled goat 
(Fab' ) 2 anti-mouse IgG antibody (GAM-FITC; Nordic, Tilburg, 
the Netherlands) for 30 min at 4°C. The relative fluorescence in­
tensity was measured by FACscan® analysis (Becton Dickinson and 
Co.).
The contribution of the LFA-l/ICAM-1 and VLA-4/ 
VCAM-1 adhesion receptor pairs in T cell-EC interactions 
was examined by binding of resting and activated T cells to 
24-h TNF-a-cultured EC, which expressed high levels of 
ICAM-1 and VCAM-1, and only low levels of ELAM-1 (Table
1). LFA-1+ T cells (JS136, PBL, CEM, and Jurkat) as well
as LFA-1“ T cells (LAD 6.6), obtained from a patient 
suffering the LAD syndrome (19), showed significant binding 
to TNF-a-stimulated EC (Fig. 1 yl). Interestingly, we ob­
served that, although approximately equal numbers of the 
different cell types bound to EC (except resting PBL), dis­
tinct receptor pairs were used to mediate adhesion. T cell 
clone JS136 and IL-2-cultured lymphocytes showed LFA-1- 
res trie ted adhesion (blocked by anti-CD 18 antibodies; Fig.
1 B). In contrast, the LFA-1" T cell clone (LAD 6.6) and 
two LFA-1 * T cell lines (CEM and Jurkat) bound to TNF- 
a-EC exclusively through VLA-4 (Fig. 1B). Compared with 
the cultured T cells, binding of freshly isolated lymphocytes 
to TNF-a-stimulated EC was significantly lower (Fig. 1 4^) 
and was mediated both by LFA-1 and VLA-4 (Fig. 1B). An­
tibodies directed against ICAM-1 and VCAM-1 blocked the 
adhesion of the cells to the same extent as anti-LFA-1 or anti- 
VLA-4 antibodies, respectively (not shown). Antibodies to 
ELAM-1 did not block the adhesion, indicating that ELAM-1 
is not involved in this process (not shown; 20). These results 
indicate that only resting PBL use both adhesion pathways 
(LFA-l/ICAM-1 and VLA-4/VCAM-1). Upon in vitro cul­
ture of PBL there is a tendency towards LFA-1-dependent/ 
VLA-4-independent adhesion, whereas fully activated T cells, 
like a T cell clone (several other T cell clones were studied; 
not shown), exclusively use LFA-1 but not VLA-4. In con-
Results and Discussion
Table 1. Expression of Cell Adhesion Molecules on Different T Cells and Endothelial Cells
mAb Antigen
Relative fluorescence intensity
T cells Cultured endothelial cells
JS136 Ly Ly IL-2 Jurkat CEM LAD 6.6 Medium 24 h TNF-a
GAM-FITC Control 2 1 1 2 3 3 2 4
SPV-L7 LFA-1 307 44 42 40 31 4 1 1
NKI-L16 LFA-1* 304 19 31 3 5 3 2 3
HP 2/1 VLA-4 74 41 30 23 46 130 1 1
F10.2 ICAM-1 40 5 21 16 14 29 44 394
4B9 VCAM-1 2 2 3 3 2 3 4 73
ENA-1 ELAM-1 3 6 5 4 4 4 6 14
Lymphocytes (Ly) were freshly isolated or cultured for 24 h with 100 U/ml IL-2 (Ly IL-2). The LFA-1+ and LFA-1" T cell clones JS136 and
LAD6.6, respectively, and the T cell lines Jurkat and CEM were cultured as described in Materials and Methods. The EC were activated by culturing
for 24 h in the presence of 100 U/ml TNF-a:. Antigen expression was determined by immunofluorescence. One representative experiment out of 
four is shown.
* Ca2+-dependent epitope.
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Figure 1. Adhesion of T cells to 24-h TNF-ex-stimulated endothelial 
cells, LFA-1+ T cells: T cell clone JS136, freshly isolated lymphocytes (Ly), 
lymphocytes cultured for 24 h with 100 U/ml IL-2 (Ly IL-2), and T cell 
lines Jurkat and CEM. LFA-1" T cells: T cell clone LAD 6.6. (A) T cells 
were 51Cr labeled and were allowed to adhere for 30 min at 37°C to 
24-h TNF-a (100 U/ml)-stimulated endothelial cells. (B) Percentage of 
inhibition of T cells to TNF-Oi-stimulated EC by anti-CD 18 antibodies 
(■) or anti-VLA-4 antibodies (^¡), showing the contribution of LFA-1, 
compared with VLA-4, in binding to EC. (C) Inhibition of a combina­
tion of anti-CD18 and anti-VLA-4 antibodies. The SE bars represent three 
independent tests within the experiment. One representative experiment 
out of four is shown.
trast to this shift from LFA-1/VLA-4-mediated adhesion to 
only LFA-1-mediated adhesion, we observed that several leu­
kemic T cell lines that express significant levels of LFA-1 (Table
1) bind EC exclusively through VLA-4. In all cases adhesion 
of T cells to TNF-a-stimulated EC could not be blocked 
completely by anti-LFA-l and anti-VLA-4 antibodies (up to 
60-80% of total adhesion; Fig. 1 C), indicating that other 
as yet undefined adhesion structures mediate the remaining 
20-40% of adhesion.
The selective use of LFA-1 or VLA-4 by T cells to mediate 
adhesion to EC prompted us to investigate the expression 
of these adhesion receptors in more detail (Table 1). All T 
cells expressed significant levels of VLA-4, indicating that 
in principle all cells are capable of using VLA-4 to mediate 
adhesion to TNF-a-stimulated EC. As expected, LFA-1 ex­
pression is totally absent on LAD T cells (LAD 6.6), thus 
explaining the VLA-4-mediated binding to TNF-a-stimulated 
EC. However, all other T cells expressed significant levels 
of LFA-1 (JS136, lymphocytes, CEM, and Jurkat). LFA-1 is 
expressed at much higher levels on JS136 compared with PBL, 
CEM, and Jurkat. Interestingly, we observed that expression 
of the L16 activation epitope, a Ca2+-dependent epitope on 
LFA-1, which recognizes a “potentially active” form of LFA-1 
(9), is absent on the LFA-1+ CEM and Jurkat T cells, 
whereas expression is low on resting lymphocytes (9) and 
high on IL-2-cultured lymphocytes and on T cell clone JS136. 
Earlier work indicated that expression of the L16 epitope-is 
a prerequisite for LFA-1 to mediate cell adhesion (9,14). This 
finding suggests that JS136 and IL-2-cultured PBL express 
a form of LFA-1 that can readily be activated to high-avidity 
ligand binding, whereas LFA-1 expressed by CEM and Jurkat 
cells lacks L16 expression and can therefore not reach its acti­
vated state, thus explaining their LFA-l-independent, VLA-4- 
mediated adhesion to TNF-a-stimulated EC. The dull ex­
pression of the L16 epitope on resting lymphocytes corre­
lates with the observation that the interaction of resting PBL 
is only partially mediated by LFA-1 since only a small number 
of the expressed LFA-1 molecules can become activated.
To determine the functional activity of the LFA-1 adhe­
sion receptors expressed on these T cells, we examined the 
capacity of these T cells to bind L cell transfectants expressing 
ICAM-1 (Fig. 2). It is known that LFA-l-mediated adhesion 
can be induced by the addition of PMA to T cells, resulting 
in high-avidity ligand binding (22). The LFA-1” T cells 
(LAD 6.6), which were used as a control, could not bind 
to L-ICAM-1 (Fig. 2). As expected, binding of L16+ JS136 
T cells and lymphocytes to L-ICAM-1 cells was induced upon 
addition of PMA, and could be blocked completely to back­
ground levels by anti-CD18 or anti-CD 54 antibodies (not 
shown). In contrast, addition of PMA to the LFA-1+ L16~ 
T cells (CEM and Jurkat) did not result in activation of LFA-1, 
because no binding to IrICAM-1 cells was observed. To ex­
clude the possibility that this was caused by the relatively 
low expression of LFA-1 on these cells (compared with JS136), 
we determined the binding capacity of PBL that were briefly 
cultured in IL-2 to express approximately similar levels of LFA-1 
as Jurkat and CEM. In contrast to the latter two cell lines,
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Figure 2. Clustering of T cells with L-ICAM-1 cells. Cells were differen­
tially labeled with fluorescent dyes. Clustering was induced with ({ )^ or 
without (■) the addition of PMA (50 ng/ml) for 45 rain at 37°C, Values 
represent means of duplicate wells. Clustering of T cells with mock- 
transfected control cells was always <10%. One experiment out of three 
is shown.
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Figure 3. Adhesion of T cells to VCAM-1, T cells were stimulated with 
(03) or without (■) anti-/3l antibody TS2/16 (10 ¿¿g/ml) for 10 min at 
4°C, Subsequently, adhesion to purified VCAM-1 was performed for 30 
min at 37°C, TS2/16-induced adhesion was blocked with an inhibitory 
anti-VLA-4 (HP2/1,10 /xg/ml) antibody (^). Adhesion to BSA was always 
<5%. One experiment out of two is shown.
these L16+ lymphocytes could readily be induced by PMA 
to bind L-ICAM-1, demonstrating that the level of LFA-1 
expression is not limiting. Also, other stimuli known to ac­
tivate LFA-1 (anti-CD2, -CD3, or the addition of Mn2+; 9,
11, 23) were incapable of inducing the activated state of the 
LFA-1 receptor on Jurkat and CEM T cells (not shown).
The results from this study demonstrate that the selective 
use of adhesion receptors in adhesion and migration of T cells 
into sites of inflammation is not only regulated by an increased 
expression of the adhesion receptors* ligands ICAM4 and 
VCAM-1 by inflammatory cytokines, such as TNF-a, but 
is also dependent on the activated state of the adhesion receptor 
itself, expressed on the T cell. Expression of the Ca2 + - 
dependent L16 epitope on LFA-1 determines if the LFA-1 
adhesion receptor is in a “potentially active” state. Because 
L16 is a Ca2+-dependent epitope, Ca2+ cations may play an 
important role in the formation of this conformation of LFA-1 
(9). If LFA-1 expressed on T cells lacks the L16 epitope, 
it cannot be triggered to create a high affinity ligand binding 
form. T o circumvent this defect these cells may use the VLA-4 
receptor VCAM-1 interaction as an alternative adhesion route, 
which is used by the LFA-1" T cells, as well as the Jurkat 
and CEM T cells. On the other hand, if LFA-1 on T cells 
expresses the L16 epitope, LFA-1 mediates adhesion to en­
dothelium, without any contribution of VLA-4 (Fig. 1). It 
is tempting to speculate that when the LFA-1 /ICAM-l in­
teraction takes place, the VLA-4/VCAM-1 contribution in 
T cell/TNF-ar-EC interaction is downregulated through an 
unknown mechanism. Work is in progress to test this hy­
pothesis.
To exclude the possibility that VLA-4 expressed on JS136 
is defective, and therefore not able to mediate adhesion to 
its ligands, we determined the capacity of VLA-4, expressed 
by these different T cells, to bind VCAM-1, a ligand of VLA-4 
(24) (Fig- 3). VLA-4 can be activated to bind VCAM-1 by 
the addition of PMA or by specific anti-/8l  antibodies that 
induce the high affinity state of VLA-4, resulting in enhanced 
binding of VLA-4 to VCAM-1 and/or FN (10, 12, 13). De­
spite the fact that VLA-4 was not equally expressed on all
T cells (Table 1), all T cells used in this study (LFA- 
1+ /L16 *, LFA-1+ /L16 ", and LFA-1 “) could be induced by 
an anti-/3l antibody (TS2/16; 10) or by PMA (data not shown) 
to bind to VCAM-1 or FN (data not shown). This induced 
interaction was completely VLA-4 mediated, since anti-VLA- 
4a antibodies blocked the interaction. These data indicate 
that in contrast to LFA-1, the VLA-4 receptor on all T cells 
used in this study can become active to bind VCAM-1, 
Moreover, binding of JS136 T cells to TNF-a-stimulated EC 
also can be enhanced by anti-/3l antibodies (10). Although 
the increase in the total number of cells bound is limited (from
50 to 60%), this is associated with a clear shift from LFA-1- 
mediated adhesion to a VLA-4/VCAM-1-media ted adhesion 
to EC (Fig. 4). However, if both LFA-1 and VLA-4 are acti­
vated through the addition of PMA, JS136 T cells primarily 
use LFA-1 and not VLA-4 to bind EC, indicating that the 
LFA-1 molecule, when activated, dominates VLA-4 in T 
cell-EC interaction (Fig. 4). The addition of PMA to CEM
anti- VLA-4 anti- LFA-1
control
TS2/16
PMA
i-1-r
40 60 80
Inhibition of T cell binding (%)
Figure 4. Contribution of LFA-1 and VLA-4 to TS2/16-induced JS136 
T cells binding to TNF-a-EC. 51Cr~labeled T cells were allowed to ad­
here for 30 min at 37°C to 24-h TNF-a-stimulated EC. Adhesion was 
induced by the addition of anti-01 antibody TS2/16 (10 /¿g/ml) or PMA 
(50 ng/ml). Basal adhesion of T cells was 50% adhesion, and was induced 
by TS2/16 and PMA up to 60%. Values are percentages of inhibition by 
the addition of anti-CD18 (■) or anti-VLA-4 (0) (10 ng/ml). One ex­
periment out of three is shown.
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or Jurkat T cells did not alter the VLA-4-dependent adhe­
sion to EC into a LFA-1-dependent adhesion, providing fur­
ther evidence that their LFA-1 molecules are not functional 
(not shown).
It should be noted that binding of T cells to isolated ligands 
(ICAM-l, VCAM-1, and FN) or ligands expressed by trans­
fected L cells is low unless the T cells are activated by PMA 
or other stimuli, inducing a high affinity state of the integrin 
receptor (9, 13, 25). Nevertheless, we consistently observed 
strong binding of the cells used in this study to EC via these 
ligands (ICAM-l and VCAM-1). This suggests that other 
interactions precede engagement of LFA-1 or VLA-4, as has 
been demonstrated for ELAM-1 (26). It can be excluded that 
E-selectin and L-selectin are involved in this process (26, 27). 
Activated T cells lack L-selectin expression, whereas E-selectin 
expression is low on EC after prolonged (24-h) exposure to 
TNF-q: (Table 1). This indicates that other, undefined mole­
cules expressed by these T cells may induce high affinity 
binding of VLA-4 or LFA-1, upon binding of TNF-a- 
stimulated EC. One possible candidate is CD31, which has 
recently been described to stimulate /3l- and j32-mediated adhe­
sion of T cell subsets to VCAM-1 and ICAM-l (28). CD31 
seems to preferentially stimulate jSl-mediated adhesion, 
whereas in our study, j32-mediated adhesion seems to domi­
nate j8l-mediated adhesion, suggesting that also other mole­
cules may be involved.
Since transendothelial migration of T cells mainly involves 
the LFA-1 /ICAM-l interaction (29), and not the VLA-4/ 
VCAM-1 interaction, the absence of the L16 epitope on LFA-1 
can have serious effects on the transendothelial migration ca­
pacity of LFA-1+L16" T cells. Indeed, it has been reported 
that migration of LFA-1" (LAD) T cells through EC is se­
verely affected by the absence of LFA-1 (30). We therefore 
assume that LFA-1+ T cells, which lack the L16 epitope, 
show binding to EC using VLA-4, but migrate poorly through 
EC. In contrast, LFA-1+ L16 + T cells will readily bind EC, 
and migrate through EC using high affinity LFA-1. This may 
provide the immune system with a mechanism by which pref­
erentially activated LFA-1 +L16+ T cells will be capable of 
migrating into tissues and actively participating in the effector 
phase of an inflammatory/immune response.
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